Tag Archives: Emerging Markets

Drug Payment Reform in China: Now That's a Mass Market

The task of building drug access for one billion new customers in China is probably this decade’s grandest public policy experiment.  It is taking place largely behind the scene in a series of often tense exchanges between Beijing and local governments – the dialogue is worth watching for the long-term commercial implications in what all […]
Posted in Emerging Markets, Global, Strategy | Also tagged , , | Leave a comment

Emerging Countries Closing in on Western R&D

UNESCO report reveals seismic shift in the world’s R&D balance. The US, Europe, and Japan may still be leading the global R&D effort, but emerging countries, especially China, are hot on their heels, says a UNESCO report launched yesterday (World Science Day). While investment in R&D is growing globally in volume, the emerging countries are […]
Posted in Emerging Markets, Global, R&D | Also tagged , | 2 Comments

Report Reveals Global Supply Chain Fears

A new report published by Axendia is calling for better collaboration with suppliers, distributors, shippers, and regulators. Global pharmaceutical outsourcing has become increasingly prevalent, but is creating a complex and risky supply chain environment that has pharmaceutical and life sciences executives on high alert, according to a new study co-sponsored by PwC and published last […]
Posted in Biotech, Emerging Markets, Global, Supply Chain | Also tagged , , , | Leave a comment

Big Pharma Reps Still Competing with Local Players in Emerging Markets

Although pharma is an increasingly global marketplace, the relative rankings of companies are becoming more localized — with significant variations — according to a new Cegedim survey of physician attitudes towards reps in the major western markets and Brazil, India, Russia, and China. According to the International Rep Quality survey, physicians tend to favor domestic […]
Posted in Emerging Markets, Europe, Guest Blog, Marketing, Sales | Also tagged , , , , , | Leave a comment

Abbott Shells Out $3.7 Billion for Piramal

In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, […]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta